Medication Burden and Rehabilitation Exercise Capacity: Clinical Implications and Evidence-Based Review

Abstract

Medication burden refers to the cumulative impact of polypharmacy on patients, particularly those with chronic illnesses requiring complex therapeutic regimens. In rehabilitation settings, medication burden can directly and indirectly affect exercise capacity, functional outcomes, and overall quality of life. This review synthesizes current evidence regarding the interplay between medication burden and rehabilitation exercise capacity, examining epidemiology, pathophysiology, risk factors, clinical features, diagnostic considerations, management strategies, emerging therapies, and current guideline recommendations. The article provides practical insights for clinicians aiming to optimize functional recovery while minimizing the adverse consequences of polypharmacy in rehabilitation patients.

Introduction

Rehabilitation medicine frequently addresses patients burdened by multiple comorbidities and a high prevalence of polypharmacy. Medication burden, defined as the cumulative effects of taking multiple medications, is increasingly recognized as a modifier of rehabilitation outcomes, particularly exercise capacity. Rehabilitation exercise capacity is a key determinant of functional independence and is closely associated with morbidity and mortality in chronic disease populations. Understanding the mechanisms by which medication burden influences exercise capacity is essential for optimizing rehabilitation strategies and improving patient outcomes. This review aims to provide clinicians with an evidence-based synthesis of the current literature, practical considerations, and guideline-based recommendations regarding medication burden and its impact on rehabilitation exercise capacity.

Epidemiology / Disease Burden

Polypharmacy, commonly defined as the use of five or more medications, is prevalent in older adults and individuals with multiple chronic conditions. Recent epidemiological studies indicate that up to 50% of rehabilitation inpatients are exposed to polypharmacy, with a significant subset experiencing hyperpolypharmacy (ten or more medications). Medication burden is particularly notable in populations with cardiovascular disease, chronic obstructive pulmonary disease (COPD), diabetes mellitus, stroke, and musculoskeletal disorders. The increasing complexity of medical management and the aging global population contribute to a growing clinical and public health challenge, as higher medication burden is linked to increased hospitalizations, adverse drug events, reduced physical function, and impaired rehabilitation outcomes.

Pathophysiology

The impact of medication burden on exercise capacity is multifactorial. Pharmacokinetic and pharmacodynamic interactions may exacerbate side effects such as dizziness, fatigue, orthostatic hypotension, and cognitive impairment, all of which can limit the ability to participate in and benefit from rehabilitation exercise. Certain drug classes, including beta-blockers, sedatives, anticholinergics, and muscle relaxants, directly affect cardiovascular, respiratory, and neuromuscular function. Cumulative anticholinergic and sedative loads have been shown to reduce maximal oxygen uptake (VO2 max), muscle strength, and balance. Additionally, medication burden may indirectly impair exercise capacity by promoting frailty, sarcopenia, and physical inactivity, creating a vicious cycle that undermines functional recovery.

Risk Factors

Risk factors for high medication burden include advanced age, multiple comorbidities, fragmented care, and lack of regular medication review. Patients with heart failure, COPD, diabetes, chronic kidney disease, and neurodegenerative disorders are especially susceptible. Social determinants of health, such as low health literacy, limited access to coordinated care, and inadequate communication among healthcare providers, further increase risk. Polypharmacy is also more likely in institutionalized or post-acute care populations, where transitions of care may result in medication discrepancies and unnecessary continuation of ineffective or harmful therapies.

Clinical Features

Clinically, medication burden may manifest as reduced exercise tolerance, increased fall risk, muscle weakness, cognitive dysfunction, and poor engagement in rehabilitation activities. Signs such as fatigue, confusion, dizziness, and postural instability should prompt review of medication regimens. The adverse effects of medication burden are often insidious and may be mistaken for progression of underlying disease or aging. Recognition of these clinical features is critical for timely intervention, prevention of complications, and optimization of rehabilitation outcomes.

Diagnosis

Diagnosis of medication burden involves comprehensive medication reconciliation and assessment of drug-drug and drug-disease interactions. Tools such as the Medication Regimen Complexity Index (MRCI), Beers Criteria, STOPP/START criteria, and anticholinergic burden scales can aid in identifying problematic regimens. Functional assessment, including standardized exercise testing (e.g., 6-minute walk test, cardiopulmonary exercise testing), should be integrated to evaluate the impact on exercise capacity. Collaboration among physicians, pharmacists, and rehabilitation specialists is essential for accurate assessment and monitoring.

Treatment & Management

Management strategies focus on minimizing unnecessary medications, optimizing therapeutic regimens, and individualizing care. Deprescribing protocols, regular medication reviews, and the use of non-pharmacological interventions can reduce medication burden. In rehabilitation settings, close monitoring for adverse effects and functional decline is warranted. Pharmacological adjustments should be guided by clinical status, patient preferences, and established guidelines. Multidisciplinary care models, including pharmacist involvement, have demonstrated efficacy in reducing medication burden and improving functional outcomes.

Recent Advances / Emerging Therapies

Recent advances include the integration of electronic health records and clinical decision support tools to flag high-risk medication regimens and facilitate deprescribing. Emerging therapies focus on precision medicine approaches, tailoring pharmacotherapy to individual genetic, phenotypic, and functional profiles. Artificial intelligence-driven medication management platforms and patient-centered deprescribing frameworks are under active investigation. Research is ongoing to determine the optimal balance between necessary pharmacotherapy and the minimization of adverse effects in the context of rehabilitation.

Guideline Recommendations

Current guidelines from organizations such as the American Geriatrics Society, European Society of Cardiology, and National Institute for Health and Care Excellence advocate for regular medication review, minimization of polypharmacy, and prioritization of non-pharmacological interventions when feasible. Rehabilitation guidelines emphasize assessing medication burden as a modifiable risk factor for poor exercise capacity and functional outcomes. Collaborative, interdisciplinary care is strongly recommended to ensure comprehensive management of medication burden in rehabilitation patients.

Conclusion

Medication burden is a significant and modifiable determinant of rehabilitation exercise capacity. Polypharmacy and complex medication regimens can hinder functional recovery through direct physiological effects and by increasing the risk of adverse events. Clinicians should maintain vigilance for signs of excessive medication burden, employ evidence-based assessment tools, and collaborate across disciplines to optimize both pharmacological therapy and rehabilitation strategies. Continued research and implementation of innovative management approaches are essential to improving outcomes for patients in rehabilitation settings.